Farewell To MedImmune: AstraZeneca Will Combine Large And Small Molecule Research
The company will integrate MedImmune, which has operated as the biologics research arm of AstraZeneca, amid an R&D and commercial restructuring.
You may also be interested in...
While leading large pharma with seven out-licensing or divestiture deals apiece during 2018, AstraZeneca and Novartis each slowed their pace somewhat. But several peer companies followed suit, as there were 31 such deals among the 20 largest biopharma firms last year.
The drug major has presented a set of financials that have comfortably surpassed analyst forecasts and show that its new oncology therapies now make up around 30% of group sales and are growing strongly.
A reorganization at the top of the UK firm brings with it controversial scientist Jose Baselga.